Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Chengdu Brilliant Inspiration Biotherapeutics was established in 2021 as part of the expansion into biological medicines by Chengdu Brilliant Pharmaceutical Group. The broader group has a robust pipeline including semaglutide biosimilar in Phase III trials for diabetes/obesity and BPR‑101 in Phase II for bacterial vaginosis. The company focuses on innovative drugs across small molecules and biologic modalities with an emphasis on unmet clinical needs.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Chengdu Brilliant Inspiration Biotherapeutics Co., Ltd..